½ÃÇè°ú¸ñº° °øÁö»çÇ×

  • ½ÃÇè¾È³»
  • ½ÃÇè°ú¸ñº° °øÁö»çÇ×

2025³âµµ Á¦3ȸ Àü¹®¾à»ç ÀڰݽÃÇè °øÁö»çÇ×

- Àå±âÀÌ½Ä -

1½ÃÇè³»¿ë ±¸¼º ¹× ½ÃÇè½Ã°£ (Àü °ú¸ñ °øÅë»çÇ×)

1)½ÃÇè³»¿ëÀº °øÅ뿵¿ª°ú Àü¹®¿µ¿ªÀ¸·Î ±¸¼ºµÊ.

  • °øÅ뿵¿ª : ÀÇÇÐÅë°è ¹× ÀǤý¾àÇÐ³í¹®ºñÆò
  • Àü¹®¿µ¿ª : Àå±âÀ̽Ä

2)½ÃÇè½Ã°£

  • ÃÑ ½ÃÇè½Ã°£ : ½ÃÇèÁغñ ¹× ¾È³», °øÁö½Ã°£ µîÀ» Æ÷ÇÔÇÏ¿© 180ºÐ(3½Ã°£).

2ÃâÁ¦À¯Çü ¹× ¹èÁ¡

1)°øÅ뿵¿ª(ÃÑ20Á¡) : °´°ü½Ä 20¹®Ç× (°¢ 1Á¡)

2)Àü¹®¿µ¿ª(ÃÑ80Á¡) : °´°ü½Ä 80¹®Ç× (°¢ 1Á¡)

  • ¾à¹°¿ä¹ýÀÇ ÀûÀý¼º °ËÅä
  • ¾à¹°¿ä¹ý °ü·Ã ¹®Á¦(drug-related problems) ÆÄ¾Ç ¹× ÇØ°á¹æ¾È Á¦½Ã
  • ȯÀÚ ¸ÂÃãÇü ¾à¹° ¼±Åà ¹× ¾à¹°¿ä¹ý °èȹ ¼ö¸³
  • ¾à¹°¿ä¹ýÀÇ Ä¡·áÈ¿°ú ¹× ¾à¹° ÀÌ»ó¹ÝÀÀ ¸ð´ÏÅ͸µ
  • ȯÀÚ º¹¾à»ó´ã ¹× ±³À°

3ÃâÁ¦¹üÀ§

1)°øÅ뿵¿ª ÃâÁ¦¹üÀ§ : ÀǾàÅë°èÀÇ ±âº»°³³ä ¹× À̸¦ Ȱ¿ëÇÑ ³í¹®Çؼ®°ú ºñÆò, ÀÓ»óÀû¿ë µî¿¡ °üÇÑ ¹®Ç×À¸·Î ÀÌ·ç¾îÁü.

  • ±Ù°Å±â¹ÝÀÇÇÐ(Evidence-Based Medicine) ¹× ±Ù°Å±â¹ÝÀÓ»ó½Ç¹«(Evidence-Based Clinical Practice, EBCP)ÀÇ ÀÌÇØ
  • ÀǾ๮ÇåÀÇ Á¾·ù ¹× Ư¡
  • ÀÓ»óÅë°èÀÇ ±âº» °³³ä
  • ³í¹®Çؼ®°ú ºñÆò, ÀÓ»óÀû¿ë

2)Àü¹®¿µ¿ª ÃâÁ¦¹üÀ§

  • Àå±âÀ̽ÄÀÇ °³³ä
  • Àå±âÀ̽İú °ü·ÃµÈ ¸é¿ª°Ë»ç
  • °¢ Àå±âº° À̽Ŀ¡ ´ëÇÑ ÀÌÇØ - ½ÅÀå ¹× ÃéÀå, °£, ½ÉÀå, Æó
  • Àå±âÀÌ½Ä È¯ÀÚ¿¡¼­ÀÇ ¾à¹°¿ä¹ý ¹× º¹¾àÁöµµ
  • °ÅºÎ¹ÝÀÀÀÇ Áø´Ü°ú Ä¡·á(±Þ¼º/¸¸¼º)
  • Àå±âÀÌ½Ä È¯ÀÚ¿¡¼­ÀÇ °¨¿° ¹× Ç×±Õ ¿ä¹ý
  • Ç÷¾×Çü ºÎÀûÇÕ ÀÌ½Ä ¹× °¨ÀÛµÈ È¯ÀÚ¿¡¼­ÀÇ À̽Ä
  • Àå±âÀÌ½Ä ÈÄ ÁßȯÀÚ ¾à¹° ¹× ¿µ¾ç¿ä¹ý
  • Àå±âÀÌ½Ä ÈÄ ÇÕº´Áõ °ü¸®
  • »õ·Î¿î ¸é¿ª¾ïÁ¦Á¦
  • °ø¿©ÀÚ ¹× ³ú»ç Àå±â±âÁõ °ü¸®

¡Ø½ÅÀ̽Ä(ÃéÀåÀÌ½Ä Æ÷ÇÔ)/°£À̽Ä/Àå±âÀÌ½Ä Àü¹Ý(90%), ½ÉÀåÀ̽Ä/ÆóÀ̽Ä(10%)

4Âü°í¹®Çå

1)Àü °ú¸ñ °øÅë Âü°í¹®Çå

°¡)¾à¹°Ä¡·áÇÐ °ü·Ã Âü°í¹®Çå

  • DiPiro JT, Yee GC, Haines ST, Nolin TD, Ellingrod VL, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 12th ed., 2023.
  • Schwinghammer TL, Koehler JM, Borchert JS, Slain D, Park SK, eds. Pharmacotherapy Casebook: A Patient-Focused Approach. 12th ed., 2023.
  • Zeind CS, Carvalho MG, Cheng JW, Zaiken K, LaPointe T, eds. Applied Therapeutics: The Clinical Use of Drugs. 12th ed., 2023.
  • Chisholm-Burns MA, Schwinghammer TL, Malone PM, Kolesar JM, Bookstaver PB, Lee KC. Pharmacotherapy Principles & Practice. 6th ed., 2022.
  • Çѱ¹ÀÓ»ó¾àÇÐȸ. ¾à¹°Ä¡·áÇÐ Á¦6°³Á¤. ½ÅÀϺϽº. 2025

³ª)°øÅ뿵¿ª(ÀÇÇÐÅë°è ¹× ÀǤý¾àÇÐ³í¹®ºñÆò) °ü·Ã Âü°í¹®Çå

  • ¾à±¹½Ç¹«ºÐ°úȸ, ¾à·áÁ¤º¸ÇÐ, ½ÅÀϺϽº, 2021³â, Section III, Á¦ 9-13Àå, 16Àå
  • ¾à±¹½Ç¹«ºÐ°úȸ, ÀÓ»ó½Ç¹«¾àÇÐ, ½ÅÀϺϽº, 2024³â, 27Àå, 29Àå
  • Guyatt G, Rennie D, Meade MO & Cook DJ. Users¡¯ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. 3rd ed., New York, USA: McGraw Hill Education & The JAMA Network. 2015.
  • DiCenzo R, ed. Clinical Pharmacist's Guide to Biostatistics and Literature Evaluation. 2nd ed., Lenexa, KS, USA: American College of Clinical Pharmacy. 2015.
  • Browner WS, Thomas B Newman TB, Cummings SR. Designing Clinical Research. 5th ed. Wolters Kluwer. 2022.
  • Malone PM, Witt BA, Malone MJ, Peterson DM. Drug Information: A Guide for Pharmacists, 7th ed. McGraw Hill. 2022.
  • Canadian Medical Association Journal (CMAJ) evidence based medicine (EBM) series
    • Wyer PC, et al. Tips for learning and teaching evidence-based medicine: Introduction to the series. CMAJ 2004;171:347-8.
    • Barratt A, et al. Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ 2004;171:353-8.
    • Montoria VM, et al. Tips for learners of evidence-based medicine: 2. Measures of precision (confidence intervals). CMAJ 2005;171:611-5.

2)Àü¹®¿µ¿ª °ü·Ã Âü°í¹®Çå

°¡)3Â÷ ¹®Çå

  • °¡Å縯ÀÇ´ë ³»°úÇб³½Ç ½ÅÀå³»°ú. ½ÅÀåÀÌ½Ä Áø·á Áöħ¼­, Á¦3ÆÇ, 2024
  • Pierre-Alain Clavien, Medical Care of the Liver Transplant Patient, 4th edition. 2012, Willy-Blackwell
  • James Neuberger et al., Liver Transplantation Clinical Assessment and Management, 2nd edition. 2021, Wiley Blackwell

³ª)°¡À̵å¶óÀÎ ¹× Àú³Î

  • ½ÅÀ̽Ä
    • Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009 Nov;9 Suppl 3:S1-155.
    • Bia M, et al. KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Kidney Dis. 2010 Aug;56(2):189-218.
    • Lentine KL, et al. KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation. 2017 Aug;101(8S Suppl 1):S1-S109.
    • Chadban SJ, et al. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation. 2020 Apr;104(4S1 Suppl 1):S11-S103.
    • Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022 Nov;102(5S):S1-S127.
    • Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021 Mar;99(3S):S1-S87.
    • Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1-59
    • Baker RJ, et al. Renal association clinical practice guideline in post-operative care in the kidney transplant recipient. BMC Nephrol. 2017 Jun 2;18(1):174.
    • Andrews PA, Burnapp L. British Transplantation Society / Renal Association UK Guidelines for Living Donor Kidney Transplantation 2018: Summary of Updated Guidance. Transplantation. 2018 Jul;102(7):e307.
    • Schinstock CA, et al. Recommended Treatment for Antibody-mediated Rejection after Kidney Transplantation: The 2019 Expert Consensus from the Transplantation Society Working Group. Transplantation. 2020 May;104(5):911-922.
    • British Transplant Society. Guidelines for Living Donor Kidney Transplantation. 2018. Available from: https://bts.org.uk/wp-content/uploads/2018/07/FINAL_LDKT-guidelines_June-2018.pdf
    • British Transplant Society. Post-Operative Care in the Kidney Transplant Recipient. 2017. Available from: https://bts.org.uk/wp-content/uploads/2017/06/FINAL_PostOperative_Care_Guideline.pdf
    • British Transplant Society. Guidelines for Antibody Incompatible Transplantation. 2015. Available from: https://bts.org.uk/wp-content/uploads/2016/09/02_BTS_Antibody_Guidelines-1.pdf
    • British Transplant Society. UK Guideline for the Management of the Patient with a Failing Kidney Transplant. 2023. Available from: https://bts.org.uk/uk-guideline-for-the-management-of-the-patient-with-a-failing-kidney-transplant
  • °£À̽Ä
    • European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2016 Feb;64(2):433-485.
    • Kok B, et al. Graft Dysfunction and Management in Liver Transplantation. Crit Care Clin. 2019 Jan;35(1):117-133.
    • Lucey MR, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013 Jan;19(1):3-26.
    • Martin P, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014 Mar;59(3):1144-1165.
    • Oh J, Kim JM. Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation. Clin Mol Hepatol. 2020;26(1):1-6.
    • British Transplant Society. Living Donor Liver Transplantation. 2015. Available from: https://bts.org.uk/wp-content/uploads/2016/09/03_BTS_LivingDonorLiver-1.pdf
  • ½ÉÀåÀ̽Ä
    • Velleca A, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2023 May;42(5):e1-e141.
    • Peled Y, et al. International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates-2024. J Heart Lung Transplant. 2024 Oct;43(10):1529-1628.e54.
    • Kobashigawa J, et al.; Consensus Conference participants. Summary of the International Society for Heart and Lung Transplantation consensus conference on emerging understanding of antibodies and antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2025 Jun 11:S1053-2498(25)01775-9.
    • Aslam S, et al.; working group members. Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement. J Heart Lung Transplant. 2020 May;39(5):418-432.
    • Husain S, et al. The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summary. J Heart Lung Transplant. 2016 Mar;35(3):261-282.
  • ÆóÀ̽Ä
    • Thompson ML, et al. Pharmacotherapy of lung transplantation: an overview. J Pharm Pract. 2013 Feb;26(1):5-13.
    • Adegunsoye A, et al. Comprehensive Care of the Lung Transplant Patient. Chest. 2017 Jul;152(1):150-164.
    • Kotecha S, et al. Review: immunosuppression for the lung transplant patient. J Thorac Dis. 2021 Nov;13(11):6628-6644.
    • Leard LE, et al. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2021;40(11):1349-1379.
    • Crespo MM, et al. ISHLT Consensus Statement on adult and pediatric airway complications after lung transplantation: Definitions, grading system, and therapeutics. J Heart Lung Transplant. 2018 May;37(5):548-563.
    • Marczin N, et al.; Task force Chairs and Writing Group. International consensus recommendations for anesthetic and intensive care management of lung transplantation. An EACTAIC, SCA, ISHLT, ESOT, ESTS, and AST approved document. J Heart Lung Transplant. 2021 Nov;40(11):1327-1348.
    • Meyer KC, et al.; ISHLT/ATS/ERS BOS Task Force Committee; ISHLT/ATS/ERS BOS Task Force Committee. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J. 2014 Dec;44(6):1479-1503.
  • ±âŸ
    • Nelson J, et al. Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and International Society for Heart and Lung Transplantation: An executive summary. Pharmacotherapy. 2022 Aug;42(8):594-598.
    • British Transplant Society. UK Guidelines on Pancreas and Islet Transplantation. 2019. Available from: https://bts.org.uk/wp-content/uploads/2019/09/FINAL-Pancreas-guidelines-FINAL-version-following-consultation.-Sept-2019.pdf
    • Battle R, et al. BSHI and BTS UK guideline on the detection of alloantibodies in solid organ (and islet) transplantation. Int J Immunogenet. 2023 Nov;50 Suppl 2:3-63.
    • American Society of Transplantation. Infectious Diseases Guidelines, 4th Edition. Clinical transplantation. 2019;33(9). Available from: https://onlinelibrary.wiley.com/toc/13990012/2019/33/9
    • British Transplant Society. UK Guideline on Prevention and Management of Cytomegalovirus (CMV) Infection and Disease Following Solid Organ Transplantation. 2022. Available from: https://bts.org.uk/uk-guideline-on-prevention-and-management-of-cytomegalovirus-cmv-infection-and-disease-following-solid-organ-transplantation
    • Kotton CN, et al.; Transplantation Society International CMV Consensus Group. The Fourth International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation. Transplantation. 2025 Jul 1;109(7):1066-1110.
    • Bhattacharya D, et al.; AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis. 2023 May 25:ciad319.
    • British Transplant Society. Hepatitis B and Solid Organ Transplantation. 2018. Available from: https://bts.org.uk/wp-content/uploads/2018/03/BTS_HepB_Guidelines_FINAL_09.03.18.pdf
    • ´ëÇѰ£ÇÐȸ. 2025 CÇü°£¿° Áø·á °¡À̵å¶óÀÎ. 2025. Available from: https://www.kasl.org/bbs/skin/guide/download.php?code=guide&number=17025
    • ´ëÇѰ£ÇÐȸ. 2022 ¸¸¼º BÇü°£¿° Áø·á °¡À̵å¶óÀÎ. 2022. Available from: https://www.kasl.org/bbs/skin/guide/download.php?code=guide&number=15609
    • Áúº´°ü¸®Ã». 2018 ¼ºÀÎ ¿¹¹æÁ¢Á¾ ¾È³»¼­. 2018. Available from: https://www.kdca.go.kr/filepath/boardDownload.es?bid=0019&list_no=142157&seq=1
    • ´ëÇѰ¨¿°ÇÐȸ. ¼ºÀο¹¹æÁ¢Á¾ °³Á¤¾È. 2023-2025. Available from: https://www.ksid.or.kr/content/info/vaccine-info.php
    • British Transplant Society. Measles Guidance. Available from: https://bts.org.uk/wp-content/uploads/2024/06/BTS-Measles-Guidance.pdf
    • ISHLT/TTS-ID. Measles Guidance for the Transplant Community. Available from: https://www.ishlt.org/education-and-publications/standards-guidelines-detail/ishlt-tts-id-measles-guidance-for-the-transplant-community
    • Johnson S, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021 Sep 7;73(5):e1029-e1044.